Boron neutron capture therapy of glioblastoma multiforme using the p- boronophenylalanine-fructose complex and epithermal neutrons
- Brookhaven National Lab., Upton, NY (United States)
- Beth Israel Medical Center, New York, NY (United States). Dept. of Neurosurgery
- Beth Israel Medical Center, New York, NY (United States). Dept. of Radiation Oncology
The amino acid analogue p-boronophenylalanine (BPA) is under investigation as a neutron capture agent for BNCT of glioblastoma multiforme. A series of patients undergoing surgical removal of tumor received BPA orally as the free amino acid. Favorable tumor/blood boron concentration ratios were obtained but the absolute amount of boron in the tumor would have been insufficient for BNCT. BPA can be solubilized at neutral pH by complexation with fructose (BPA-F). Studies with rats suggest that intraperitoneal injection of BPA-F complex produces a much higher tumor boron concentration to rat intracerebral 9L gliosarcoma that were possible with oral BPA. Higher boron concentrations have allowed higher tumor radiation doses to be delivered while maintaining the dose to the normal brain vascular endothelium below the threshold of tolerance. The experience to date of the administration of BPA-F to one patient is provided in this report.
- Research Organization:
- Brookhaven National Lab. (BNL), Upton, NY (United States)
- Sponsoring Organization:
- USDOE Office of Energy Research, Washington, DC (United States)
- DOE Contract Number:
- AC02-76CH00016
- OSTI ID:
- 419224
- Report Number(s):
- BNL-63407; CONF-9410281-9; ON: DE97000005; TRN: 97:001765
- Resource Relation:
- Conference: 6. international symposium on neutron capture therapy for cancer, Kobe (Japan), 31 Oct - 4 Nov 1994; Other Information: PBD: [1994]
- Country of Publication:
- United States
- Language:
- English
Similar Records
Comparative assessment of single-dose and fractionated boron neutron capture therapy
Boron neutron capture therapy of ocular melanoma and intracranial glioma using p-boronophenylalanine